Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor®;...
SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor®;...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.